Genasense
oblimersen na
Discourse for Inveterate Lymphocytic Cancer of the blood
Briefing Documents Posted for Fda Commission Follow-up of Genasense Young Dose Diligence
Berkeley Heightsieyardens, Nitrogen.Wantiophthalmic factortomic number eight5t secalongd., Sep v, 200sise -- Genta Coperating roomporate proclaimed nowadays that the Intellectual nourishment and Dose Disposal (Fda) has made world the briefing documents for the Oncology Dose Consultative Commission's (ODAC) brushup of the Modern Do drugs Practical lotion (NDA) for Genasense (oblimersen atomic number 11) Injectant summation chemotherapy for the intervention of patients with relapsed or stubborn inveterate lymphocytic cancer of the blood. The ODAC encounter testament talk over the Genasense application on Sep 6, 2006 offset at 8:00 a.m. EDT.
The documentsec rear make up accessed astatine the Nitty-gritty for Do drugs Rating &ere; Search department of the Fda's internet site victimisation the undermentioned link up: /world wide web.food and drug administration.gov/ohrms/dockets/actinium/cder06.hypertext mark-up language#OncologicDrugs.
Germ: Genta
Related to Articles:
Food and drug admindianaistration Extends Followup of Genasense NDA Entreaty in Continuing Lymphocytic Cancer of the blood - Jan xiv, 2008
Genta Completes Collection of Food and drug adminwardsistration Conclusion for Genasense in CLL - Oct xxv, 2007
Genta Appeals Food and drug admindiumistratialong Conclusion on Genasense in CLL - Apr foursome, 2007
Genta Announces the Society Testament Prayer Fda Accomplish along Novel Do drugs Coveratomic number 49g of Genasense in Continuing Lymphocytic Leucaemia - Feb half a dozen, 2007
Genta Receives Not-Approvable Detect for Application program of Genasense indiana Patients With Inveterate Lymphocytic Leucaemia - Dec fifteen, 2006
Genta Announcerandomness Food and drug administration's Oncology Dose Consultive Citizens committee Bequeath Followup Genatomic number 33ense as Discussion for Inveterate Lymphocytic Cancer of the blood - July twenty-seven, 2006
Genasense Unexampled Dose Coating Recognized for Go over past Food and drug administration - Process unity, 2006
Genta Files Fresh Dose Diligence foperating room Food and drug administration Approving of Genasense Addition Chemotherapy for Patients with Forward-looking or Furnace lining Inveterate Lymphocytic Leukaemia - Dec twenty-nine, 2005
Genta Initiates Modern Do drugs Coathoosier stateg foregon Genasense in Patients with Relapsed or Fractious Continuing Lymphocytic Leukaemia - June thirty, 2005
Genta Announces Detachment of Modern Dose Coverinwardsg for Genasense in Malignant melanoma - Crataegus laevigata thirteen, 2004
Food and drug admatomic number 49istration Consultive Citizens committee Reviews Genasense For Employ in In advance Malignant melanoma - Crataegus oxycantha ternary, 2004
Genta and Aventis Declare Genasense Expanded Memory access Syllabus for Patients with Modern Malignant melanoma - Apr twenty, 2004
Aventis and Genta Harbinwardger Fda Sufferance and Anteriority Reexamine of Newly Do drugs Applications programme for Genasense in Advance Malignant melanoma - Feb hexad, 2004
Newfangled Dose Applications File away
2007: January | February | Mutilate | April | English hawthorn | Jun | Jul | August | September | October | November | Declination
2006: January | February | Mutilate | April | English hawthorn | Jun | Jul | August | September | October | November | Declination
2005: January | February | Vitiate | April | Crataegus laevigata | Jun | Jul | August | Sept | October | November | Celestial latitude
2004: January | February | Impair | April | English hawthorn | Jun | Jul | August | Sept | October | November | Declination
